CVM Orders Centaurus to Make R$6 Billion OPA for Oncoclínicas
The regulator’s board reversed its technical staff and imposed a buyout that could far exceed the stock’s market value while an arbitration challenge runs in parallel.
Overview
- The CVM collegial board voted unanimously on Tuesday to require U.S. manager Centaurus to launch a mandatory public takeover offer (OPA) for Oncoclínicas shares.
- The order could force Centaurus to pay more than R$6 billion, implying an OPA price above R$16 per share compared with the current trading price near R$1.50.
- CVM technical staff had recommended the IPO-era exception in paragraph 8 of article 39 applied and that no statutory OPA was required, but the directors overruled that view.
- Centaurus filed for arbitration against rival manager Latache just before the CVM vote and the fund says the B3 arbitration chamber has exclusive jurisdiction, a move that may delay or complicate enforcement.
- Beyond the immediate cash impact, the decision sets a governance precedent for how bylaw thresholds and IPO-era exceptions are read in Brazil and could affect minority protections and recovery outcomes at Oncoclínicas.